July 12, 2012
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that it has received a transparency declaration from Fidelity Management & Research Company LLC in accordance with the Belgian Law of
2 May 2007
concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market.
ThromboGenics NV has received a transparency notification from Fidelity Management & Research Company LLC having its registered office at Devonshire Street 82,
indicating that, following the acquisition of shares, its participation in the company exceeds the 3% threshold. As of today, ThromboGenics has 35,691,432 shares outstanding.
Fidelity Management & Research Company LLC holds 1,092,051 shares, or 3.05 % of all outstanding shares.
ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company's lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic Vitreomacular Adhesion (VMA), otherwise termed Vitreomacular Traction (VMT), including when associated with macular hole. The MAA for ocriplasmin has been accepted for review in
and in the U.S. the FDA has accepted the BLA filing and granted it Priority Review.
, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside
the United States
. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments, plus an attractive level of royalties on Alcon's net sales of ocriplasmin. ThromboGenics and Alcon intend to share the costs equally of developing ocriplasmin for a number of new vitreoretinal indications.
ThromboGenics is also developing TB-403, a novel antibody therapeutic, in collaboration with BioInvent International, for cancer and non-cancer, including ophthalmology, indications.